- Home
- DMAC vs VIGL Comparison
DMAC vs VIGL Comparison
Compare DMAC & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- VIGL
- Stock Information
- Founded
- DMAC 2000
- VIGL 2020
- Country
- DMAC United States
- VIGL United States
- Employees
- DMAC N/A
- VIGL N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- DMAC Health Care
- VIGL Health Care
- Exchange
- DMAC Nasdaq
- VIGL Nasdaq
- Market Cap
- DMAC 158.1M
- VIGL 134.9M
- IPO Year
- DMAC N/A
- VIGL 2022
- Fundamental
- Price
- DMAC $4.11
- VIGL $7.89
- Analyst Decision
- DMAC Strong Buy
- VIGL Buy
- Analyst Count
- DMAC 2
- VIGL 7
- Target Price
- DMAC $8.00
- VIGL $8.00
- AVG Volume (30 Days)
- DMAC 102.4K
- VIGL 2.4M
- Earning Date
- DMAC 05-13-2025
- VIGL 05-07-2025
- Dividend Yield
- DMAC N/A
- VIGL N/A
- EPS Growth
- DMAC N/A
- VIGL N/A
- EPS
- DMAC N/A
- VIGL N/A
- Revenue
- DMAC N/A
- VIGL N/A
- Revenue This Year
- DMAC N/A
- VIGL N/A
- Revenue Next Year
- DMAC N/A
- VIGL N/A
- P/E Ratio
- DMAC N/A
- VIGL N/A
- Revenue Growth
- DMAC N/A
- VIGL N/A
- 52 Week Low
- DMAC $2.14
- VIGL $1.31
- 52 Week High
- DMAC $6.82
- VIGL $7.95
- Technical
- Relative Strength Index (RSI)
- DMAC 50.90
- VIGL 90.42
- Support Level
- DMAC $3.92
- VIGL $2.23
- Resistance Level
- DMAC $4.33
- VIGL $7.95
- Average True Range (ATR)
- DMAC 0.29
- VIGL 0.13
- MACD
- DMAC 0.02
- VIGL 0.56
- Stochastic Oscillator
- DMAC 56.79
- VIGL 98.95
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.